Arthneeti

Marksans Pharma Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Published 13 Jun 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹12.3K Cr

Marksans Pharma targets to double revenue in the next 3 to 5 years, aiming for INR4,000 crores by FY28. - Growth drivers include strong expansion in the U.S. Marksans Pharma aims to double its revenue in the next 3 to 5 years, targeting INR4,000 crores by FY28. - Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) margin guidance remains stable at around 20-22%, despite raw material inflation pressures. - Profit after tax and Earnings Per Share (EPS) showed strong growth in FY26 with a 64.3% increase in PAT and EPS reaching INR9.2. - The company expects continued growth driven by diversification into new geographies like Europe (Germany, Canada), strong U.S.

From Marksans Pharma Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Price

₹321

Market Cap

₹12.3K Cr

P/E Ratio

29.4

Revenue Rank

Rank 3

Margin Rank

Rank 3

How does Marksans Pharma Ltd rank in Pharmaceuticals & Biotechnology?

Compare Marksans Pharma Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.

Revenue: Rank 3Margin: Rank 3
View Pharmaceuticals & Biotechnology leaderboard →

Marksans Pharma Ltd — Quarterly revenue & net profit

Revenue Net Profit
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹856 Cr, net profit ₹149 Cr.

Full financials →

📊 Revenue & Sales Performance

Rank 3
  • →Marksans Pharma targets to double revenue in the next 3 to 5 years, aiming for INR4,000 crores by FY28.
  • →Growth drivers include strong expansion in the U.S. market, Europe (especially U.K. and Germany), and Australia/New Zealand.
  • →Australia is expected to reach $100 million in revenue within 3 years, with ongoing new product launches.
  • →Europe and Canada markets are being developed organically, with product filings underway and revenue expected to start trickling in by late FY27.
  • →Capacity utilization currently about 50-55%, with spare capacity to support growth before expansion.
  • →The company plans to file over 200 products in the U.K. over the next 4 years, expanding the product pipeline continuously.
  • →Revenue growth guidance is conservatively 15-20% annually in near term.
  • →Growth across all geographies is expected, with U.S. as the primary driver, but Europe and Australia gaining importance.

See what Marksans Pharma Ltd said on profitability & margins — free account, 30 seconds.

🏗️ Capital Expenditure Plans

Yes
  • →Capex during FY26 was INR131 crores, primarily for the new facility and ongoing maintenance.
  • →Major capex cycle now complete, with free cash flow generation improving steadily.
  • →Planning additional capex within the Teva facility to launch different dosage forms not currently available.
  • →Management actively exploring acquisition targets for strategic growth; ongoing due diligence on two potential targets.
  • →2027 expected to see some M&A activity funded by INR990 crores cash balance.
  • →Focus on value-accretive acquisitions across different geographies, conservatively valued to ensure return on investment.
  • →No current plans for buying remaining stake in Australia/New Zealand entity as partners are effectively growing the business.
  • →Capacity expansions planned but currently have spare capacity; land bank expansion or new plants under consideration for future scale-up.

See what Marksans Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.

📋 Order Book & Pipeline

No information
The transcript from Marksans Pharma Limited's Q4 FY26 investor/analyst meet does not explicitly mention the current or expected order book or pending orders. However, some related points to their business outlook and growth plans include: - Strong growth in multiple geographies like U.S., Europe (including U.K.), Australia, and Canada with an expanding product pipeline. - A healthy and growing product pipeline, with about 50+ new products expected for filing in the U.S. in FY27 and larger pipelines in other geographies. - Canada products are under filing with expected approvals in late FY26. - Australia/New Zealand business targeting $100 million revenue milestone within 3 years. - Focus on acquiring and integrating new assets in key geographies to diversify platforms. - Continuing to build inventory to mitigate supply chain uncertainties and geopolitical risks. - Management confident of doubling revenue in the next 3 to 5 years. No specific order book or pending order figures were disclosed.

Key Metrics

Revenue

Rank 3

Margin

Rank 3

Capex

Yes

Fundraise

No information

Order Book

No information

Continue your research

What Marksans Pharma Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Torrent Pharmaceuticals Ltd (Q4 FY26)

    Consolidated revenue for Q4 FY26 up 42%, EBITDA up 41%, margins stable at ~32% (Page 2). Key concall takeaways from Torrent Pharma.'s Q4 FY26 earnings call…

  • Kwality Pharmaceuticals Ltd (Q4 FY26)

    FY26: Achieved INR503 crores revenue; oncology contributed INR100-120 crores. Key concall takeaways from Kwality Pharmaceuticals Ltd's Q4 FY26 earnings call…

  • RPG Life Sciences Ltd (Q4 FY26)

    Domestic formulation growth driven by strong volume expansion (~9.8% volume growth in Q4 FY26 vs 1.1% industry) and new product launches (5.1% growth vs 2%…

  • Sai Parenterals Ltd (Q4 FY26)

    Long-term growth supported by over 50% revenue from long-term CDs contracts in regulated markets. Key concall takeaways from Sai Parenteral's's Q4 FY26…

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Marksans Pharma Ltd Q4 FY26 results?

Marksans Pharma targets to double revenue in the next 3 to 5 years, aiming for INR4,000 crores by FY28. - Growth drivers include strong expansion in the U.S. Marksans Pharma aims to double its revenue in the next 3 to 5 years, targeting INR4,000 crores by FY28. - Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) margin guidance remains stable at around 20-22%, despite raw material inflation pressures. - Profit after tax and Earnings Per Share (EPS) showed strong growth in FY26 with a 64.3% increase in PAT and EPS reaching INR9.2. - The company expects continued growth driven by diversification into new geographies like Europe (Germany, Canada), strong U.S.

What is Marksans Pharma Ltd share price analysis?

Marksans Pharma Ltd currently shows a below-average growth signal. The stock trades at a P/E of 29.4 with a market cap of ₹12,265 Cr. Investors should review the full earnings analysis for detailed insights.

Is Marksans Pharma Ltd planning capital expenditure?

Capex during FY26 was INR131 crores, primarily for the new facility and ongoing maintenance.

Keep Marksans Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.